158 related articles for article (PubMed ID: 37558851)
21. Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.
Le M; Garcilazo Y; Ibáñez-Juliá MJ; Younan N; Royer-Perron L; Benazra M; Mokhtari K; Houillier C; Hoang-Xuan K; Alentorn A
Oncologist; 2019 Sep; 24(9):e898-e904. PubMed ID: 30867243
[TBL] [Abstract][Full Text] [Related]
22. A novel prognostic model based on pretreatment serum albumin and ECOG PS for primary CNS lymphoma: an international, multi-center study.
Wei L; Gao Y; Prochazka KT; Liu R; Wang L; Liu B; He Y; Bertero L; Pellerino A; Cassoni P; Tamagnone L; Deutsch AJ; Zhan H; Lai J; Kim SJ; You H
J Neurooncol; 2023 Jun; 163(2):301-311. PubMed ID: 37231231
[TBL] [Abstract][Full Text] [Related]
23. Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients.
Ghesquières H; Drouet Y; Sunyach MP; Sebban C; Chassagne-Clement C; Jouanneau E; Honnorat J; Biron P; Blay JY
Hematol Oncol; 2013 Jun; 31(2):57-64. PubMed ID: 22886543
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in primary central nervous system lymphomas.
Ferreri AJ; Reni M
Hematol Oncol Clin North Am; 2005 Aug; 19(4):629-49, vi. PubMed ID: 16083827
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
26. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy.
Lee J; Shishido-Hara Y; Suzuki K; Shimizu S; Kobayashi K; Kamma H; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2017 Oct; 47(10):925-934. PubMed ID: 28981733
[TBL] [Abstract][Full Text] [Related]
28. A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis.
Wu Z; Wang C; Lyu Y; Lin Z; Lu M; Wang S; Wang B; Yang N; Li Y; Wang J; Duan X; Zhang N; Gao J; Zhang Y; Hao M; Wang Z; Gao G; Liang R
Front Oncol; 2023; 13():1104425. PubMed ID: 37056341
[TBL] [Abstract][Full Text] [Related]
29. Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial.
Zeremski V; Koehler M; Fischer T; Schalk E
Ann Hematol; 2016 Apr; 95(5):793-9. PubMed ID: 26801791
[TBL] [Abstract][Full Text] [Related]
30. Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.
Chalise L; Motomura K; Ohka F; Hirano M; Hara M; Nishimura Y; Natsume A; Wakabayashi T
Anticancer Res; 2017 Sep; 37(9):5215-5223. PubMed ID: 28870957
[TBL] [Abstract][Full Text] [Related]
31. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
33. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
[TBL] [Abstract][Full Text] [Related]
35. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
Jang JE; Kim YR; Kim SJ; Cho H; Chung H; Lee JY; Park H; Kim Y; Cheong JW; Min YH; Kim JS
Eur J Cancer; 2016 Apr; 57():127-35. PubMed ID: 26918738
[TBL] [Abstract][Full Text] [Related]
36. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ; Blay JY; Reni M; Pasini F; Spina M; Ambrosetti A; Calderoni A; Rossi A; Vavassori V; Conconi A; Devizzi L; Berger F; Ponzoni M; Borisch B; Tinguely M; Cerati M; Milani M; Orvieto E; Sanchez J; Chevreau C; Dell'Oro S; Zucca E; Cavalli F
J Clin Oncol; 2003 Jan; 21(2):266-72. PubMed ID: 12525518
[TBL] [Abstract][Full Text] [Related]
37. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
[TBL] [Abstract][Full Text] [Related]
38. Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India.
Das S; Bagal B; Jain H; Kashyap L; Anbarasan S; Abhishek S; Bondili S; Nayak L; Thorat J; Mirgh S; Gokarn A; Punatar S; Ayushi S; Epari S; Tembhare P; Shetty P; Khanna N; Goda J; Aliasgar M; Gupta T; Sengar M; Khattry N; Laskar S; Menon H
Indian J Hematol Blood Transfus; 2023 Jan; 39(1):57-70. PubMed ID: 36699441
[TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma.
Ouyang T; Wang L; Zhang N; Zhang Z; Xiong Y; Li M; Hong T
World Neurosurg; 2020 Jul; 139():e508-e516. PubMed ID: 32311566
[TBL] [Abstract][Full Text] [Related]
40. Machine learning-based pathomics signature of histology slides as a novel prognostic indicator in primary central nervous system lymphoma.
Duan L; He Y; Guo W; Du Y; Yin S; Yang S; Dong G; Li W; Chen F
J Neurooncol; 2024 Jun; 168(2):283-298. PubMed ID: 38557926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
